Literature DB >> 17907963

c-Jun N-terminal kinases as potential therapeutic targets.

Baljinder Salh1.   

Abstract

One principal aim of research in the signal transduction field is to identify targets for therapeutic intervention, in an attempt to modify disease and curtail human suffering. Diseases such as chronic inflammation, atherosclerosis, diabetes and cancer exact a huge toll on health, in physical, social and financial terms. Defective signaling mechanisms are central to their pathogenesis. One candidate signaling molecule that is presently undergoing intense investigation is the c-Jun N-terminal kinase. With roles described in almost all classes of disease, the main questions are what type of inhibitor to use and when exactly to use it during the disease course?

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907963     DOI: 10.1517/14728222.11.10.1339

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  10 in total

1.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

Review 2.  Endoplasmic reticulum enrollment in Alzheimer's disease.

Authors:  Ricardo J S Viana; Ana F Nunes; Cecília M P Rodrigues
Journal:  Mol Neurobiol       Date:  2012-07-20       Impact factor: 5.590

3.  Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling.

Authors:  Anastasia Z Kalea; Fiona See; Evis Harja; Maria Arriero; Ann Marie Schmidt; Barry I Hudson
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

4.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 5.  Signal integration by JNK and p38 MAPK pathways in cancer development.

Authors:  Erwin F Wagner; Angel R Nebreda
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 6.  Transcriptional regulation of cytokine function in airway smooth muscle cells.

Authors:  Deborah Clarke; Gautam Damera; Maria B Sukkar; Omar Tliba
Journal:  Pulm Pharmacol Ther       Date:  2009-04-22       Impact factor: 3.410

7.  ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.

Authors:  Kristin A D Sauter; Eli A Magun; Mihail S Iordanov; Bruce E Magun
Journal:  Cancer Biol Ther       Date:  2010-08-13       Impact factor: 4.742

8.  Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.

Authors:  Ke Zheng; Sarah Iqbal; Pamela Hernandez; HaJeung Park; Philip V LoGrasso; Yangbo Feng
Journal:  J Med Chem       Date:  2014-11-21       Impact factor: 7.446

9.  JNK Inhibition Inhibits Lateral Line Neuromast Hair Cell Development.

Authors:  Chengfu Cai; Jinchao Lin; Shaoyang Sun; Yingzi He
Journal:  Front Cell Neurosci       Date:  2016-02-05       Impact factor: 5.505

10.  Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells.

Authors:  Hoi-Hin Kwok; Po-Ying Poon; Siu-Ping Fok; Patrick Ying-Kit Yue; Nai-Ki Mak; Michael Chi-Wai Chan; Joseph Sriyal Malik Peiris; Ricky Ngok-Shun Wong
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.